|
MechanismEGFR T790M inhibitors [+3] |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Clinical study to evaluate the safety, tolerability, immunogenicity, and preliminary efficacy of a tumor vaccine targeting specific EGFR mutations as monotherapy and combination therapy in patients with EGFR-mutated non-small cell lung cancer
/ Not yet recruitingNot Applicable Exploring the Safety, Tolerability, and Efficacy of BBM040 in the Treatment of Human Papillomavirus (HPV) Infection
A prospective study of reRNA™ HPV tumor vaccine alone or in combination with immune checkpoint inhibitors in patients with HPV16/18-positive unresectable recurrent or metastatic solid tumors
100 Clinical Results associated with The First Affiliated Hospital of Nanyang Medical College
0 Patents (Medical) associated with The First Affiliated Hospital of Nanyang Medical College
100 Deals associated with The First Affiliated Hospital of Nanyang Medical College
100 Translational Medicine associated with The First Affiliated Hospital of Nanyang Medical College